Playin’ It Safe: KKR, Cinven, say word to safety with Arle Capital, report says

More: On Teddy Forstmann

More Tragedy: Prospect’s Barkas dies suddenly

It’s Not Looking so super for Netflix

Especially with the arrival of this

Is It Us? The Fed looks to edit the U.S. economy into prosperity

Oh You’re Naughty: Not shockingly, Jimmy Fallon is not the funniest thing on Jimmy Fallon

Looking Stateside: ICG considers first US mezz fund after four years investing there

Power Failure: Investments into India’s power sector slow down

Property No More: Nomura is in talks to sell its real estate arm

Chinese Dream: Dreamworks Animation in talks to set up joint venture with Shanghai Media Group and China Media Capital to invest up to $2 billion in Chinese animation market

On Your Marks: Get set, accelerate!

DFINE Inc., a maker of minimally invasive radiofrequency targeted therapies for the treatment of vertebral pathologies, closed a $25 million. Investors include OrbiMed Advisors, Prospect Venture Partners, Split Rock Partners, BBT Fund/Apothecary Capital, Highland Capital Management and Vanguard Ventures.

Third Rock Ventures, Prospect Venture Partners and Yasuda Enterprise Development Corp. have poured $27 million into privately held biotechnology company TOPICA Pharmaceuticals. The Series B round will be used for continued development of the company’s broad-spectrum topical antifungal agent, the company said Tuesday.

Panmira Pharmaceuticals has appointed Hari Kumar as chief executive officer. Panmira was spun out of Amira Pharmaceuticals prior to Amira’s acquisition by Bristol-Myers Squibb. Investors include Dr. Brad Bolzon (Versant Ventures), Mr. Kevin Kinsella (Avalon Ventures), Dr. David Schnell (Prospect Venture Partners) and Dr. Heath Lukatch (Novo A/S).

Azelon Pharmaceuticals, formerly known as Zelos Therapeutics, has raised $4.5 million in Series A financing as part of a corporate restructuring, the company announced Tuesday. Prospect Venture Partners led the round. Other Azelon investors are Lighthouse Capital Partners and Covington Venture Fund.

Attention venerable venture funds: Limited partners don’t give a hoot about how long you’ve been in business. The only number they care about these days is your internal rate of return. The latest firm to learn that lesson is Prospect Venture Partners, a biopharmaceutical and medical device investor founded in 1997. Prospect has released its [...]

KYTHERA Biopharmaceuticals Inc., a company developing products in aesthetic medicine, has closed on $37.4 million in Series D financing. KYTHERA’s investors include Versant Ventures, ARCH Venture Partners, Prospect Venture Partners, JAFCO, Partner Funds management, INVUS Financial Advisors, BBT Capital Management, and Altitude Life Science Ventures. Also joining the syndicate were Foley Ventures and Latham and Watkins. KYTHERA has now raised more than $108 million to date.

Bristol-Myers Squibb Co. will acquire privately held Amira Pharmaceuticals in an all-cash transaction worth up to $475 million. The deal includes $325 million upfront, with potential additional milestone payments totaling $150 million, the companies announced Thursday. Amira Pharmaceuticals was backed by investors including Novo A/S, Avalon Ventures, Prospect Venture Partners and Versant Ventures.

Uncertainties around health care reform and the complexities of medical reimbursement weighed heavily on the business models of most presenting companies at this week’s J.P. Morgan Healthcare Conference. Not so, however, for Kythera Biopharmaceuticals, a Calabasas, Calif.-based developer of cosmetic treatments that took the stage yesterday to talk up prospects for what it sees as [...]

NinePoint Medical has completed a $33 Million Series A financing round, led by Third Rock Ventures and Prospect Venture Partners. The money will be used to develop innovative broad-based medical platforms for pathology devices. The company is also moving to new corporate headquarters in Cambridge, Mass.